多酚杂志

This study employs combined network pharmacology and molecular docking approaches to investigate the potential  mechanisms by which Erigeron breviscapus polyphenols inhibit liver fibrosis. Active compounds were identified through  literature mining, with targets predicted using TCMSP, PubChem, SwissTarget, and SwissADME databases. Liver fi brosis related targets were retrieved from GeneCards, OMIM, and TTD. Following rigorous screening, 12 bioactive polyphenolic  compounds and 117 corresponding targets were identifi ed, intersecting with 8,375 liver fi brosis targets to yield 67 common  targets. Protein-protein interaction analysis revealed 80 key targets (e.g., EGFR, ESR1, PTGS2). GO and KEGG analyses  indicated enrichment in 352 biological terms and 50 pathways, including chemical carcinogenesis receptor activation and  steroid hormone biosynthesis. Molecular docking confirmed effective binding affinity between the top four compounds (by degree value) and their respective targets. In summary, the results of this study indicate that Erigeron breviscapus can inhibit  the development of liver fibrosis and related diseases through multiple components, targets, and pathways. This study provides a solid theoretical basis for the research of Erigeron breviscapus in the fi eld of anti liver fibrosis.